Patent ID: 7435718

Claim:
A composition comprising a CXCR4 antagonist selected from the group consisting of: 1) a first SDF-1 analog having CXCR4 antagonist activity consisting of: (i) an N-terminal region consisting of from 14 to about 17 amino acids that comprise a conserved KGVS (residues 1-4 in SEQ ID NO:1) motif in residue positions 1-4, and a conserved CPCRFF (residues 9-14 in SEQ ID NO:1) in residue positions 9-14; (ii) a C-terminal region consisting of LKWIQEYLEKALN (residues 55-67 in SEQ ID NO:1); and (iii) a linker consisting of either 4 natural amino acids or an aminoalkanoic acid having up to 20 carbons, where the linker connects the N-terminal region to the C-terminal region to form the CXCR4 antagonist; and 2) a second SDF-1 analog having CXCR4 antagonist activity, said second SDF-1 analog consisting of the first SDF-1 analog having conservative amino acid substitutions, wherein the conservative amino acid substitutions occur in any of residues 9-14 of the N-terminal region or the C-terminal region; and wherein the first or second SDF-1 analog is optionally modified with an acyl group, acetyl group, an amide group, a detectable substance, a modifier capable of reducing the ability of the analog to act as a substrate for carboxypeptidases, or a modifier capable of reducing the ability of the analog to act as a substrate for aminopeptidases.